Full-Time

Product Management-Agentic Science Platform Director

Updated on 6/3/2026

Generate Biomedicines

Generate Biomedicines

201-500 employees

Develops on-demand medicines using generative biology

Compensation Overview

$140k - $196k/yr

+ Bonus + Equity

Cambridge, MA, USA

In Person

Category
Product
Required Skills
LLM
Product Management
Requirements
  • 7+ years of product management experience, ideally including platform or AI-enabled products
  • Experience working in fast paced, constantly evolving environments within biotech, pharma, and/or tech
  • Strong understanding of and hands-on experience with LLMs, AI agents and evaluation methods
  • Hands on experience with continuous discovery, user research, and prototype development for validating both problems and solutions
  • Strong external orientation - aware of the fast-evolving AI and scientific tooling landscape
  • Track record of influencing cross-functional teams without formal authority
  • Excellent communication skills - able to bridge scientists, engineers, and executives
  • Ability to foster an inclusive, collaborative environment and build relationships and trust with a diverse set of stakeholders
  • Bachelor’s degree (or equivalent experience) in computational sciences, applied mathematics, life sciences, engineering, or a related field
  • Advanced degree preferred but not required
Responsibilities
  • Advance the agentic science vision: Build on and evolve the product strategy for Generate’s agentic platform across the full drug discovery lifecycle
  • Identify high-value scientific workflows that are ripe for agentification
  • Translate company goals into measurable product outcomes tied to scientific productivity, cycle time, and data leverage.
  • Expand and scale Generate’s internal agentic science infrastructure: Partner with Engineering and Scientific teams to build core agentic infrastructure: Tool orchestration frameworks; Workflow automation layers; Agent evaluation and benchmarking systems; Interfaces into biological data platforms
  • Establish principles for agent reliability, validation, governance, and safety in scientific contexts in collaboration with cross-functional teams.
  • Develop the external ecosystem strategy: Map the external landscape of agentic tools, AI copilots, workflow automation platforms, and scientific AI startups
  • Identify build vs buy vs partner opportunities
  • Lead evaluation, pilot programs, onboarding, and integration of external tools and partners
  • Drive cross-functional adoption: Work deeply with scientists across early discovery and clinical development to embed agentic solutions into real workflows
  • Run continuous discovery efforts to identify friction points and opportunity spaces
  • Influence change management, innovation and drive adoption of new capabilities
  • Lead end-to-end product execution: Own roadmap prioritization and define success metrics and feedback loops for agentic performance and impact
  • Communicate progress, trade-offs, and outcomes clearly to executive stakeholders
  • Continuously refine product development processes to match the speed of AI innovation
Desired Qualifications
  • Advanced degree preferred but not required
Generate Biomedicines

Generate Biomedicines

View

Generate Biomedicines uses generative biology to design medicines with its Generate Platform, combining machine learning, biological engineering, and medicine. The platform analyzes millions of proteins to learn how natural function is encoded and then designs and produces medicines with specific therapeutic functions, enabling on-demand protein and drug design across multiple therapeutic areas. It differentiates itself by blending a scalable, data-driven design process with hands-on biology to move drug discovery from purely exploratory work to proactive on-demand creation, with a goal of democratizing biotherapeutics. The company's aim is to make medicines faster, more accessible, and available across diverse therapeutic areas.

Company Size

201-500

Company Stage

IPO

Headquarters

Somerville, Massachusetts

Founded

2018

Simplify Jobs

Simplify's Take

What believers are saying

  • Phase 3 GB-0895 creates a near-term asthma readout.
  • $516.6 million cash funds operations into early 2028.
  • Amgen and Novartis collaborations already generate revenue and validation.

What critics are saying

  • Phase 3 GB-0895 failure would damage the platform thesis immediately.
  • Early clinical GB-4362 and GB-5267 still lack human proof-of-concept.
  • Persistent losses force dependence on capital markets and partner renewals.

What makes Generate Biomedicines unique

  • Generate builds proteins with generative biology, not conventional screening.
  • GB-0895 is the first next-gen TSLP asset to reach Phase 3.
  • The platform spans antibodies, enzymes, peptides, and stealth proteins.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Generate Biomedicines who can refer or advise you

Benefits

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
AIToolboard
Apr 9th, 2026
AI's rising stars: 7 startups shaping 2026 & beyond.

AI's rising stars: 7 startups shaping 2026 & beyond. Discover the groundbreaking AI startups poised to dominate 2026! From generative biology to personalized education, AI ToolBoard spotlight the innovators you ne AIToolboard TeamAuthor April 9, 2026 0 views The artificial intelligence landscape is evolving at a breathtaking pace. While established tech giants continue to invest heavily in AI, it's the nimble, innovative startups that are often pushing the boundaries of what's possible. As of April 9, 2026, several emerging companies are demonstrating exceptional promise, poised to disrupt industries and redefine its interaction with technology. This post dives into seven of these AI startups to watch, analyzing their core technologies, potential impact, and what makes them stand out. The generative biology revolution: BioGenesis AI. The convergence of AI and biotechnology is arguably the most exciting frontier in tech. BioGenesis AI is leading the charge in generative biology, using advanced machine learning models to design novel proteins and therapeutic molecules. Unlike traditional drug discovery, which is often slow and expensive, BioGenesis AI can rapidly prototype and test potential candidates in silico, significantly accelerating the development process. * Their core technology leverages a proprietary Generative Adversarial Network (GAN) architecture trained on a massive dataset of protein structures and biological interactions. * BioGenesis AI recently announced a partnership with NovaPharm, a leading pharmaceutical company, to develop a new class of cancer immunotherapies. * Key differentiator: Their ability to predict protein folding with unprecedented accuracy, reducing the risk of failed clinical trials. * Actionable Insight: Keep an eye on their publications in Nature Biotechnology and Science for updates on their research. Personalized education at scale: LearnFlow Dynamics. One-size-fits-all education is becoming a relic of the past. LearnFlow Dynamics is revolutionizing learning through AI-powered personalized education platforms. Their system analyzes a student's learning style, knowledge gaps, and emotional state in real-time, adapting the curriculum and teaching methods accordingly. Adaptive learning & Emotional AI. LearnFlow's platform isn't just about delivering content; it's about understanding how a student learns best. * They utilize a combination of Natural Language Processing (NLP) to assess student understanding and Computer Vision to detect engagement levels. * The platform integrates with existing Learning Management Systems (LMS) like Canvas and Moodle, making it easy for schools to adopt. * Unique Feature: Their "Emotional AI" component identifies signs of frustration or boredom and adjusts the learning pace or content accordingly. * Practical Advice: Educators should explore LearnFlow's pilot programs to see how personalized learning can improve student outcomes. The future of Robotics: Agile Robotics Systems. Robotics has long promised to automate tasks and improve efficiency, but many robots lack the adaptability needed for real-world applications. Agile Robotics Systems is tackling this challenge with AI-powered robots that can learn and adapt to dynamic environments. Reinforcement learning & dexterous manipulation. Agile Robotics' robots utilize advanced reinforcement learning algorithms to master complex tasks, such as assembly, packaging, and logistics. * Their robots are equipped with highly sensitive tactile sensors and advanced computer vision systems, allowing them to "feel" and "see" their surroundings. * They've secured major contracts with Amazon and Tesla to automate warehouse operations and manufacturing processes. * Competitive Advantage: Their robots require minimal programming and can quickly adapt to new tasks. * Consider this: The decreasing cost of sensors and computing power is making Agile Robotics' technology increasingly accessible. AI-Driven cybersecurity: ShieldAI Technologies. Cyber threats are becoming more sophisticated and frequent. ShieldAI Technologies is developing AI-powered cybersecurity solutions that can proactively detect and respond to attacks in real-time. * Their platform uses machine learning to identify anomalous behavior and predict potential threats before they can cause damage. * ShieldAI's "Autonomous Threat Hunter" automatically investigates and neutralizes threats without human intervention. * Key Innovation: Their use of federated learning allows them to train their models on data from multiple sources without compromising privacy. * For Businesses: Implementing AI-driven cybersecurity solutions like ShieldAI's is no longer a luxury, but a necessity. Hyper-Personalized marketing: Nova Insights. Marketing is becoming increasingly personalized, and Nova Insights is leading the way with AI-powered marketing automation tools. Their platform analyzes customer data to create highly targeted campaigns that deliver the right message to the right person at the right time. Predictive analytics & Customer Journey mapping. Nova Insights goes beyond basic segmentation, using predictive analytics to anticipate customer needs and behaviors. * They offer a suite of tools for email marketing, social media advertising, and website personalization. * Their "Customer Journey Mapper" visualizes the entire customer experience, identifying opportunities to improve engagement and conversion rates. * Standout Feature: Their ability to integrate with a wide range of marketing platforms, including Salesforce, HubSpot, and Marketo. * Marketing Professionals: Explore Nova Insights' case studies to see how they've helped other businesses achieve significant ROI. AI for sustainable agriculture: TerraSense Analytics. Addressing global food security requires innovative solutions. TerraSense Analytics is using AI to optimize agricultural practices, reduce waste, and improve crop yields. * Their platform analyzes data from drones, satellites, and sensors to provide farmers with real-time insights into soil conditions, crop health, and weather patterns. * TerraSense's "Precision Irrigation" system automatically adjusts watering schedules based on plant needs, conserving water and reducing costs. * Impactful Technology: Their work is contributing to more sustainable and efficient farming practices. * Farmers & Agribusiness: Consider implementing TerraSense's solutions to improve crop yields and reduce environmental impact. The ai-powered legal assistant: LexiCorp AI. The legal industry is ripe for disruption. LexiCorp AI is developing AI-powered tools that automate legal research, document review, and contract analysis. * Their flagship product, "LexiAssist," uses NLP to quickly and accurately identify relevant case law and statutes. * LexiCorp's "Contract Analyzer" automatically reviews contracts for potential risks and liabilities. * Efficiency Gains: LexiCorp's tools are helping lawyers save time and money, allowing them to focus on more strategic work. * Legal Professionals: Explore LexiCorp's free trial to see how their tools can streamline your workflow. Key takeaways. * Generative AI is expanding beyond text and images: BioGenesis AI demonstrates its power in biology. * Personalization is paramount: LearnFlow Dynamics and Nova Insights are tailoring experiences for individuals. * Robotics is becoming more adaptable: Agile Robotics Systems is creating robots that can learn and evolve. * AI is crucial for cybersecurity: ShieldAI Technologies is proactively defending against evolving threats. * Sustainability is a key driver of innovation: TerraSense Analytics is optimizing agriculture for a greener future. * AI is transforming traditionally conservative industries: LexiCorp AI is modernizing the legal field. Conclusion. These seven startups represent just a small fraction of the exciting innovation happening in the AI space today. As AI technology continues to mature, AI ToolBoard can expect to see even more groundbreaking companies emerge, transforming industries and shaping the future. Staying informed about these emerging players is crucial for anyone interested in the future of technology and its impact on its world. The next few years promise to be a period of rapid growth and disruption, and these are the companies leading the charge. AIToolboard Team Published April 9, 2026 AI Companies Discover 1,300+ AI tools, browse job opportunities, and stay updated with the latest AI trends.

Yahoo Finance
Mar 8th, 2026
Generate Biomedicines shares drop 11% as $250M loss sparks valuation concerns

Generate Biomedicines has experienced share price weakness, declining 10% over the past week and 11.38% year-to-date to $11.21. The company reported revenue of $31.89 million against a net loss of $249.52 million, reflecting costs of developing its generative biology platform and early-stage protein therapeutics pipeline. The stock currently trades at a price-to-sales ratio of 44.8 times, well above the US biotechnology industry average of 12 times and peer group average of 19 times. This valuation suggests investors are pricing in significant future growth from the company's generative biology platform. The elevated multiple sets a high bar for commercial execution, particularly given the company's substantial ongoing losses and early-stage development programmes. Sentiment could shift quickly if trials encounter setbacks or funding conditions tighten.

Alabama Now
Feb 27th, 2026
Generate Biomedicines prices $400M IPO at $16 per share on Nasdaq

Generate Biomedicines, a clinical-stage generative biology company using AI for drug design and development, has priced its initial public offering at $16.00 per share. The Somerville, Massachusetts-based company is offering 25 million shares, expecting to raise $400 million in gross proceeds before fees and expenses. Underwriters have a 30-day option to purchase an additional 3.75 million shares. Generate's shares are expected to begin trading on the Nasdaq Global Select Market on 27 February 2026 under ticker symbol "GENB", with the offering closing on 2 March 2026. Goldman Sachs and Morgan Stanley are serving as joint lead book-running managers, with Piper Sandler, Guggenheim Securities and Cantor as book-running managers.

RamaOnHealthcare
Feb 5th, 2026
Generate, an AI-driven Flagship startup, pitches an IPO

Generate, an ai-driven Flagship startup, pitches an IPO. The biotech, which raised more than $800 million privately on the promise of artificial intelligence-aided drug discovery, is developing a potential competitor to the asthma treatment Tezspire. * Generate Biomedicines, a well-funded startup banking on the promise of artificial intelligence in drug development, filed papers for an initial public offering on Wednesday. * Founded by the prolific company creator Flagship Pioneering in 2018, Generate has been steadily raising money and inking partnerships while harnessing AI to generate experimental therapies. The company says it has raised $805 million from sales of preferred stock and brought in $110 million in payments from collaborations with Novartis and Amgen. * Now, it's looking to take the next step in an environment that...

BioSpace
Jan 9th, 2025
Generate:Biomedicines Provides Update on its Platform and Pipeline Powered by AI at the 43rd Annual J.P. Morgan Healthcare Conference

Generate:Biomedicines provides update on its platform and pipeline powered by AI at the 43rd Annual J.P. Morgan Healthcare Conference.